Commentary on ACCP position statement on the use of microdosing in the drug development process [1]

Journal of Clinical Pharmacology

Volumn 47, Issue 12, 2007, Pages 1595-1596

  Rowland, Malcolm ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; CYTOCHROME P450 3A4; DIAZEPAM; ERYTHROMYCIN; MIDAZOLAM; UNCLASSIFIED DRUG; WARFARIN; ZK 253;

ACCELERATOR MASS SPECTROMETRY; BLOOD SAMPLING; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SYNTHESIS; ENZYME POLYMORPHISM; HUMAN; LETTER; MASS SPECTROMETRY; NONHUMAN; PHARMACOKINETICS;

BIOMEDICAL RESEARCH; CLINICAL TRIALS AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; PHARMACOLOGY, CLINICAL; SOCIETIES, SCIENTIFIC;

EID: 36148960050     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270007310548     Document Type: Letter

References (4)

1. Bertino JS, Greenberg HE, Reed MD American College of Clinical Pharmacology position statement on the use of microdosing in the drug development process. J Clin Pharmacol. 2007 ; 47: 418-422.
2. Lappin G., Kuhnz H., Jochemsen R., et al. Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with five drugs. Clin Pharmacol Ther. 2006 ; 80: 203-217.
3. Jones HM, Parrott N., Jorga K., Lave T. A novel strategy for physiologically based predictions of human pharmacokinetics. Clin Pharmacokinet. 2006 ; 45: 511-542.
4. Gueorguieva II, Nestorov IA, Rowland M. Fuzzy modeling and simulation of pharmacokinetic models: case study of whole body physiologically based model of diazepam. J Pharmacokinet Pharmacodyn. 2004 ; 31: 185-213.